Journal article
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia
R Delahunty, M Lee, HL Wong, J Johns, J Mckendrick, B Lee, S Kosmider, P Cooray, S Ananda, J Desai, B Tran, J Tie, P Gibbs, R Wong
Internal Medicine Journal | WILEY | Published : 2020
DOI: 10.1111/imj.14288
Abstract
Background: In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival. The addition of biologic agents (bevacizumab and cetuximab/panitumumab) further improves survival. The uptake of available systemic agents for mCRC in routine practice in Australia is poorly described. Methods: The ACCORD database was interrogated to determine demographics, treatments and outcomes for patients diagnosed with mCRC between 1 January 2011 and 1 January 2016 at six Melbourne centres. Results: About 1130 mCRC patients were identified: median age was 69 years (range 26–105); 61% had s..
View full abstract